Navigation Links
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea

-- Primary endpoint achieved --

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA (SWX:COPN) announced today positive preliminary results from its phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic antibiotic that is not absorbed when taken in tablet form. Through the use of Cosmo's MMX(tm) technology, which delivers the active ingredient into the colon, bacteria in the gastro intestinal tract that are important for vitamin synthesis are not sterilized. Given that it is practically not absorbed CB-01-11 is potentially applicable for the treatment of long term infections in the colon.

In the placebo controlled, randomized, double blind trial 120 patients in 8 sites in South Africa were treated with a 200mg tablet, 4 times per day for 3 days. The trial assessed non-inferiority versus Normix® (rifaximin) and the primary endpoint was the time from first ingestion of tablet to the last unformed stool. According to the preliminary reports CB-01-11 met this primary endpoint.

Mauro Ajani, CEO of Cosmo Pharmaceuticals, commented: "We are very encouraged about these preliminary results since many of the needs of patients are not adequately met with products currently on the market. Infections of the colon affect many more persons than colon inflammations and this is consequently a substantially larger market. We believe that our proprietary MMX(tm) technology will enable us to improve a range of products in colon infections and thus better meet patients' requirements."

Further analysis of the data is ongoing.

About Cosmo Pharmaceuticals

Cosmo is a speciality pharma company that aims to become a global leader in optimised therapies for certain gastrointestinal diseases. The com­pany's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulce
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:12/1/2008)...ll/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ...world,s leading medical journals, results of clini...imental compound tasimelteon (VEC-162). The publi...in agonist tasimelteon (VEC-162) for transient ins...olled multicentre trials." Results are reported fr...
(Date:12/1/2008)...wo-way switch that, if turned off, causes lymphati...y lose their identity and become more like blood e... Scientists at St. Jud...t a certain differentiated cell type is so ready t...t expression of a gene called Prox1 to dissuade ...
(Date:12/1/2008)...GeoVax Labs, Inc.,(OTC Bulletin Board: GOVX), an ...man vaccines for diseases caused by HIV-1 (Human I...s, announced today that the launch of its Phase 2a...ites across North and South America.,These trials...Institutes of,Health (NIH), and the HIV Vaccine T...
(Date:11/28/2008)...l/ -- Eli Lilly and Company,(NYSE: LLY ) has wi...A) from,the U.S. Food and Drug Administration (FD...ement of chronic pain. Lilly plans to resubmit the...ta from a recently completed positive study,in ch...e decision does not affect duloxetine,s FDA-approv...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 1Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 2Gilead to Topple GSK as the Top Player in the Anti Infectives Drug Market in 2014 9132 3Forterus Inc Announces Stock Buyback 29598 1Forterus Inc Announces Stock Buyback 29598 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 1The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 2The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 3The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 29596 4Innovative Wellness Project Launched in Four Maine School Districts 29592 1Innovative Wellness Project Launched in Four Maine School Districts 29592 2
(Date:12/2/2008)... 2 The Healthcare group at,Frost ... is pleased to announce that,it will be hosting a...,sub-Saharan Africa on Friday 12 December at 16h0...om.com/cgi-bin/prnh/20081117/FSLOGO ) , Med...services is a,relatively novel concept in most su...
(Date:12/2/2008)...athon Health, a leading provider of onsite health ...hat New Balance, the athletic products company, ha...nd manage onsite health clinics and to provide hea...in Maine , Burlington, VT...ading provider of onsite employee health services ...
(Date:12/2/2008)... many families, the problem with the holidays is f...ight into how caregivers of aging parents can brin...experience. , San Mateo, ...he stress of the holiday season is family, especia...xpert Esther Koch , founder of Encore Management...
(Date:12/2/2008)...ional Non-profit Launches Age-related Macular Dege...ost to Eligible Patients and Free Eye-Healthy Cook... (Vocus) December 2, 2008 -- "Do You See What...isease known as Age-related Macular Degeneration (... ,Picture this…. a large black hole in the ...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3
...ewed journal of American Cancer Society) reveals t...t clinically significant screening// criteria for ...uding major depression and post-traumatic stress d...ally all of the women admitted have been experienc...
...hat has FDA approval for treating rheumatoid arthr...ith juvenile rheumatoid// arthritis, according to ...ge of Rheumatology Annual Scientific Meeting in Wa...adalimumab, currently used to treat adults with mo...
...detect synacthen, which when injected simulates th...steroid. This is// most common in sports where spo...-enhancing tool. Synacthen and injecting performan... other than medical treatment is banned. Though ...
...und that pregnant women with systemic lupus are at...ions compared to normal// pregnant women. The stu...ted nationwide covering more than 18 million women...n with systemic lupus should be considered a high-...
Other Medicine News:Health News:Breast Cancer Patients Suffer From Psychological Problems 2Health News:Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis 2Health News:Sports Cheats Beware - New Test To Detect Synacthen Found 2Health News:Pregnant Women With Lupus Are At Greater Risk 2Health News:Pregnant Women With Lupus Are At Greater Risk 3
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists.
...fety Knife with BD Xstar Blade includes a speciall...tects the blade in prodedure and handling. The Xs...ess for manufacturing surgical blades. This propr...nsistency. The arch style, single-bevel geometry ...
Electric high speed system.
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm.
Medicine Products: